XNK Therapeutics AB a yau ta sanar da cewa an yi wa mai haƙuri na farko magani a cikin wani binciken asibiti na Phase II ta amfani da XNK's manyan autologous natural killer (NK) na tushen dan takara magani a hade tare da Sanofi's anti-CD38 antibody Sarclisa (Isatuximab).
"Samun mara lafiya na farko da aka bi da shi tare da kwayoyin NK a cikin wannan binciken na asibiti wani muhimmin mahimmanci ne a cikin ci gaban asibiti na babban dan takarar mu na miyagun ƙwayoyi," in ji Johan Aschan, CMO na XNK Therapeutics. "Binciken yana ci gaba da kyau, kuma muna sa ran samun sakamako."
Mai binciken na yanzu-wanda aka ƙaddamar, buɗewa, bazuwar, sarrafawa, nazarin Mataki na II ISA-HC-NK (EudraCT: 2020-000994-26) yana kwatanta babban maganin ɗan takara na XNK tare da Sanofi's anti-CD38 antibody Isatuximab tare da Isatuximab kadai azaman maganin ƙarfafawa biyo baya. autologous stem cell transplantation a cikin marasa lafiya tare da sabon kamuwa da cutar myeloma da yawa. Nazarin asibiti yana faruwa ne a Asibitin Jami'ar Karolinska a wurin Huddinge kuma ya ƙunshi jimillar marasa lafiya 60 tare da marasa lafiya 30 a kowane hannun jiyya.
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- “Having the first patient treated with NK cells in this clinical study is an important milestone in the clinical development of our leading drug candidate,”.
- The clinical study takes place at the Karolinska University Hospital at its Huddinge site and encompasses at total of 60 patients with 30 patients in each treatment arm.
- XNK Therapeutics AB a yau ta sanar da cewa an yi wa mai haƙuri na farko magani a cikin wani binciken asibiti na Phase II ta amfani da XNK's manyan autologous natural killer (NK) na tushen dan takara magani a hade tare da Sanofi's anti-CD38 antibody Sarclisa (Isatuximab).
